Madecassoside (Standard)

Madecassoside (Standard) is the analytical standard of Madecassoside. This product is intended for research and analytical applications. Madecassoside is a pentacyclic triterpene isolated from Centella asiatica and has anti-inflammatory properties. Antioxidant and anti-aging effects. Madecassoside is a pentacyclic triterpene isolated from Centella asiatica. Madecassoside is orally active and has inhibitory properties against inflammation, oxidation, apoptosis and autophagy. Madecassosid inhibits activities of p38 MAPK and NF-kB[5][6], exhibits an anti-apopototic property, activates Nrf2 expression to reduce the neurotoxicity[10]. Madecassoside can be used in endocrine diseases, cardiovascular diseases, skin diseases and other diseases.

Product Specifications

CAS Number

[34540-22-2]

Product Name Alternative

Asiaticoside A (Standard)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; Autophagy; Caspase; Endogenous Metabolite; Keap1-Nrf2; p38 MAPK; Reference Standards

Type

Reference Standards

Related Pathways

Apoptosis; Autophagy; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB; Others

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Endocrinology; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease; Others

Assay Protocol

https://www.medchemexpress.com/madecassoside-standard.html

Purity

99.09

Smiles

O=C(C1(CCC(C)C2C)C2C3=CCC4C(C)(CC(O)C5C4(CC(O)C(O)C5(C)CO)C)C3(C)CC1)OC(C(C(O)C6O)O)OC6COC(C(C(O)C7OC(OC(C)C(O)C8O)C8O)O)OC7CO

Molecular Formula

C48H78O20

Molecular Weight

975.12

Precautions

H302, H315, H319, H335

References & Citations

[1]Zexin Li et al. Madecassoside suppresses proliferation and invasiveness of HGF-induced human hepatocellular carcinoma cells via PKC-cMET-ERK1/2-COX-2-PGE2 pathway. Int Immunopharmacol. 2016 Apr;33:24-32.|[2]Xia Y et al. Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice through promoting the generation of hepatocyte growth factor via PPAR-γ in colon. Br J Pharmacol. 2016 Apr;173 (7) :1219-35|[3]Su Z et al. Protective effects of madecassoside against Doxorubicin induced nephrotoxicity in vivo and in vitro. Sci Rep. 2015 Dec 14|[4]Anukunwithaya, et al., Pharmacokinetics of a Standardized Extract of Centella asiatica ECa 233 in Rats. Planta Med. 2017 May;83 (8) :710-717. |[5]Bian D, et al., Madecassoside, a triterpenoid saponin isolated from Centella asiatica herbs, protects endothelial cells against oxidative stress. J Biochem Mol Toxicol. 2012 Oct;26 (10) :399-406.|[6]Luo Y, et al., Neuroprotective effects of madecassoside against focal cerebral ischemia reperfusion injury in rats. Brain Res. 2014 May 27;1565:37-47.|[7]Ling Y, et al., Protective effect of madecassoside on H2O2-induced oxidative stress and autophagy activation in human melanocytes. Oncotarget. 2017 May 7;8 (31) :51066-51075.|[8]Elhassen SAM, et al., Effect of madecassoside and catalpol in amelioration of insulin sensitivity in pancreatic (INS-1E) β-cell line. Nat Prod Res. 2021 Nov;35 (22) :4627-4631.|[9]Du B, et a; ., Madecassoside prevents Aβ (25-35) -induced inflammatory responses and autophagy in neuronal cells through the class III PI3K/Beclin-1/Bcl-2 pathway. Int Immunopharmacol. 2014 May;20 (1) :221-8.|[10]Liu S, et al., Madecassoside ameliorates lipopolysaccharide-induced neurotoxicity in rats by activating the Nrf2-HO-1 pathway. Neurosci Lett. 2019 Sep 14;709:134386.|[11]Lu GX, et al., Madecassoside ameliorates bleomycin-induced pulmonary fibrosis in mice by downregulating collagen deposition. Phytother Res. 2014 Aug;28 (8) :1224-31.